Gilead Sciences Inc.’s new spin-out company to sell authorized generics of its hepatitis C fixed-dose combination products Harvoni and Epclusa was packaged as offering potential out-of-pocket savings to patients – and it could do so – but the gambit should also draw market share away from AbbVie Inc. among US government-insured patients.
Foster City, Calif.-based Gilead announced Sept. 24 that it is launching the subsidiary Asegua Therapeutics LLC to sell authorized generics...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
